## **AGENDA**

## ALABAMA MEDICAID AGENCY PHARMACY AND THERAPEUTICS (P&T) COMMITTEE

## May 4, 2022 1:00 p.m. – 3:00 p.m.

3. Pharmacy program update		
<ul> <li>4. Oral presentations by manufacturers/manufacturers' representatives (prior to each respective class review)</li> <li>5. Pharmacotherapy class re-reviews</li></ul>	2.	Approval of February 9, 2022 P&T Committee Meeting minutes
(prior to each respective class review)  5. Pharmacotherapy class re-reviews		
<ul> <li>Pharmacotherapy class re-reviews</li></ul>	4.	
<ul> <li>Mineralocorticoid (Aldosterone) Receptor Antagonists – AHFS 243220</li> <li>Central Alpha-Agonists – AHFS 240816</li> <li>Direct Vasodilators – AHFS 240820</li> <li>Peripheral Adrenergic Inhibitors – AHFS 240832</li> <li>Hypotensive Agents, Miscellaneous – AHFS 240892</li> <li>Alpha-Adrenergic Blocking Agents – AHFS 242000</li> <li>Beta-Adrenergic Blocking Agents – AHFS 242400</li> <li>Dihydropyridines – AHFS 242808</li> <li>Calcium-Channel Blocking Agents, Miscellaneous – AHFS 242892</li> <li>Angiotensin-Converting Enzyme Inhibitors – AHFS 243204</li> <li>Angiotensin II Receptor Antagonists – AHFS 243208</li> <li>Renin Inhibitors – AHFS 243240</li> <li>Loop Diuretics – AHFS 402808</li> <li>Potassium-Sparing Diuretics – AHFS 402816</li> <li>Thiazide Diuretics – AHFS 402820</li> <li>Thiazide-Like Diuretics – AHFS 402824</li> <li>Vasopressin Antagonists – AHFS 402828</li> <li>Diuretics, Miscellaneous – AHFS 402892</li> <li>Alzheimer's Agents  <ul> <li>Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current brands to be included: Aricept®, Exelon®, and Razadyne ER® only)</li> <li>Central Nervous System Agents, Miscellaneous – AHFS Class 289200 (current brands to be included: Aduhelm®, Namenda®, Namenda XR®, and Namzaric® only)</li> </ul> </li> <li>6. New Business</li> <li>Results of voting announced</li></ul>	_	
<ul> <li>Direct Vasodilators – AHFS 240820</li> <li>Peripheral Adrenergic Inhibitors – AHFS 240832</li> <li>Hypotensive Agents, Miscellaneous – AHFS 240892</li> <li>Alpha-Adrenergic Blocking Agents – AHFS 242000</li> <li>Beta-Adrenergic Blocking Agents – AHFS 242400</li> <li>Dihydropyridines – AHFS 242808</li> <li>Calcium-Channel Blocking Agents, Miscellaneous – AHFS 242892</li> <li>Angiotensin-Converting Enzyme Inhibitors – AHFS 243204</li> <li>Angiotensin II Receptor Antagonists – AHFS 243208</li> <li>Renin Inhibitors – AHFS 243240</li> <li>Loop Diuretics – AHFS 402808</li> <li>Potassium-Sparing Diuretics – AHFS 402816</li> <li>Thiazide Diuretics – AHFS 402820</li> <li>Thiazide-Like Diuretics – AHFS 402828</li> <li>Diuretics, Miscellaneous – AHFS 402892</li> <li>Alzheimer's Agents  <ul> <li>Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current brands to be included: Aricept®, Exelon®, and Razadyne ER® only)</li> <li>Central Nervous System Agents, Miscellaneous – AHFS Class 289200 (current brands to be included: Aduhelm®, Namenda®, Namenda XR®, and Namzaric® only)</li> </ul> </li> <li>New Business</li> <li>Results of voting announced</li></ul>	5.	
<ul> <li>Peripheral Adrenergic Inhibitors – AHFS 240832</li> <li>Hypotensive Agents, Miscellaneous – AHFS 240892</li> <li>Alpha-Adrenergic Blocking Agents – AHFS 242000</li> <li>Beta-Adrenergic Blocking Agents – AHFS 242400</li> <li>Dihydropyridines – AHFS 242808</li> <li>Calcium-Channel Blocking Agents, Miscellaneous – AHFS 242892</li> <li>Angiotensin-Converting Enzyme Inhibitors – AHFS 243204</li> <li>Angiotensin II Receptor Antagonists – AHFS 243208</li> <li>Renin Inhibitors – AHFS 243240</li> <li>Loop Diuretics – AHFS 402808</li> <li>Potassium-Sparing Diuretics – AHFS 402816</li> <li>Thiazide Diuretics – AHFS 402820</li> <li>Thiazide-Like Diuretics – AHFS 402824</li> <li>Vasopressin Antagonists – AHFS 402828</li> <li>Diuretics, Miscellaneous – AHFS 402892</li> <li>Alzheimer's Agents  <ul> <li>Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current brands to be included: Aricept®, Exelon®, and Razadyne ER® only)</li> <li>Central Nervous System Agents, Miscellaneous – AHFS Class 289200 (current brands to be included: Aduhelm®, Namenda®, Namenda XR®, and Namzaric® only)</li> </ul> </li> <li>New Business  <ul> <li>Results of voting announced</li> <li>Next meeting dates</li> <li>August 10, 2022</li> <li>November 9, 2022</li> </ul> </li> </ul>		<ul> <li>Central Alpha-Agonists – AHFS 240816</li> </ul>
<ul> <li>Hypotensive Agents, Miscellaneous – AHFS 240892</li> <li>Alpha-Adrenergic Blocking Agents – AHFS 242000</li> <li>Beta-Adrenergic Blocking Agents – AHFS 242400</li> <li>Dihydropyridines – AHFS 242808</li> <li>Calcium-Channel Blocking Agents, Miscellaneous – AHFS 242892</li> <li>Angiotensin-Converting Enzyme Inhibitors – AHFS 243204</li> <li>Angiotensin II Receptor Antagonists – AHFS 243208</li> <li>Renin Inhibitors – AHFS 243240</li> <li>Loop Diuretics – AHFS 402808</li> <li>Potassium-Sparing Diuretics – AHFS 402816</li> <li>Thiazide Diuretics – AHFS 402820</li> <li>Thiazide-Like Diuretics – AHFS 402828</li> <li>Diuretics, Miscellaneous – AHFS 402828</li> <li>Diuretics, Miscellaneous – AHFS 402892</li> <li>Alzheimer's Agents <ul> <li>Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current brands to be included: Aricept®, Exelon®, and Razadyne ER® only)</li> <li>Central Nervous System Agents, Miscellaneous – AHFS Class 289200 (current brands to be included: Aduhelm®, Namenda®, Namenda XR®, and Namzaric® only)</li> </ul> </li> <li>6. New Business <ul> <li>Results of voting announced</li></ul></li></ul>		<ul> <li>Direct Vasodilators – AHFS 240820</li> </ul>
<ul> <li>Hypotensive Agents, Miscellaneous – AHFS 240892</li> <li>Alpha-Adrenergic Blocking Agents – AHFS 242000</li> <li>Beta-Adrenergic Blocking Agents – AHFS 242400</li> <li>Dihydropyridines – AHFS 242808</li> <li>Calcium-Channel Blocking Agents, Miscellaneous – AHFS 242892</li> <li>Angiotensin-Converting Enzyme Inhibitors – AHFS 243204</li> <li>Angiotensin II Receptor Antagonists – AHFS 243208</li> <li>Renin Inhibitors – AHFS 243240</li> <li>Loop Diuretics – AHFS 402808</li> <li>Potassium-Sparing Diuretics – AHFS 402816</li> <li>Thiazide Diuretics – AHFS 402820</li> <li>Thiazide-Like Diuretics – AHFS 402828</li> <li>Diuretics, Miscellaneous – AHFS 402828</li> <li>Diuretics, Miscellaneous – AHFS 402892</li> <li>Alzheimer's Agents <ul> <li>Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current brands to be included: Aricept®, Exelon®, and Razadyne ER® only)</li> <li>Central Nervous System Agents, Miscellaneous – AHFS Class 289200 (current brands to be included: Aduhelm®, Namenda®, Namenda XR®, and Namzaric® only)</li> </ul> </li> <li>6. New Business <ul> <li>Results of voting announced</li></ul></li></ul>		<ul> <li>Peripheral Adrenergic Inhibitors – AHFS 240832</li> </ul>
<ul> <li>Alpha-Adrenergic Blocking Agents – AHFS 242000</li> <li>Beta-Adrenergic Blocking Agents – AHFS 242400</li> <li>Dihydropyridines – AHFS 242808</li> <li>Calcium-Channel Blocking Agents, Miscellaneous – AHFS 242892</li> <li>Angiotensin-Converting Enzyme Inhibitors – AHFS 243204</li> <li>Angiotensin II Receptor Antagonists – AHFS 243208</li> <li>Renin Inhibitors – AHFS 243240</li> <li>Loop Diuretics – AHFS 402808</li> <li>Potassium-Sparing Diuretics – AHFS 402816</li> <li>Thiazide Diuretics – AHFS 402820</li> <li>Thiazide-Like Diuretics – AHFS 402824</li> <li>Vasopressin Antagonists – AHFS 402828</li> <li>Diuretics, Miscellaneous – AHFS 402892</li> <li>Alzheimer's Agents <ul> <li>Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current brands to be included: Aricept®, Exelon®, and Razadyne ER® only)</li> <li>Central Nervous System Agents, Miscellaneous – AHFS Class 289200 (current brands to be included: Aduhelm®, Namenda®, Namenda XR®, and Namzaric® only)</li> </ul> </li> <li>6. New Business</li> <li>Results of voting announced</li></ul>		1
<ul> <li>Beta-Adrenergic Blocking Agents – AHFS 242400</li> <li>Dihydropyridines – AHFS 242808</li> <li>Calcium-Channel Blocking Agents, Miscellaneous – AHFS 242892</li> <li>Angiotensin-Converting Enzyme Inhibitors – AHFS 243204</li> <li>Angiotensin II Receptor Antagonists – AHFS 243208</li> <li>Renin Inhibitors – AHFS 243240</li> <li>Loop Diuretics – AHFS 402808</li> <li>Potassium-Sparing Diuretics – AHFS 402816</li> <li>Thiazide Diuretics – AHFS 402820</li> <li>Thiazide-Like Diuretics – AHFS 402824</li> <li>Vasopressin Antagonists – AHFS 402828</li> <li>Diuretics, Miscellaneous – AHFS 402892</li> <li>Alzheimer's Agents  <ul> <li>Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current brands to be included: Aricept<sup>®</sup>, Exelon<sup>®</sup>, and Razadyne ER<sup>®</sup> only)</li> <li>Central Nervous System Agents, Miscellaneous – AHFS Class 289200 (current brands to be included: Aduhelm<sup>®</sup>, Namenda<sup>®</sup>, Namenda XR<sup>®</sup>, and Namzaric<sup>®</sup> only)</li> </ul> </li> <li>6. New Business</li> <li>Results of voting announced</li></ul>		
<ul> <li>Dihydropyridines – AHFS 242808</li> <li>Calcium-Channel Blocking Agents, Miscellaneous – AHFS 242892</li> <li>Angiotensin-Converting Enzyme Inhibitors – AHFS 243204</li> <li>Angiotensin II Receptor Antagonists – AHFS 243208</li> <li>Renin Inhibitors – AHFS 243240</li> <li>Loop Diuretics – AHFS 402808</li> <li>Potassium-Sparing Diuretics – AHFS 402816</li> <li>Thiazide Diuretics – AHFS 402820</li> <li>Thiazide-Like Diuretics – AHFS 402824</li> <li>Vasopressin Antagonists – AHFS 402828</li> <li>Diuretics, Miscellaneous – AHFS 402892</li> <li>Alzheimer's Agents <ul> <li>Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current brands to be included: Aricept®, Exelon®, and Razadyne ER® only)</li> <li>Central Nervous System Agents, Miscellaneous – AHFS Class 289200 (current brands to be included: Aduhelm®, Namenda®, Namenda XR®, and Namzaric® only)</li> </ul> </li> <li>New Business <ul> <li>Results of voting announced</li></ul></li></ul>		
<ul> <li>Calcium-Channel Blocking Agents, Miscellaneous – AHFS 242892</li> <li>Angiotensin-Converting Enzyme Inhibitors – AHFS 243204</li> <li>Angiotensin II Receptor Antagonists – AHFS 243208</li> <li>Renin Inhibitors – AHFS 243240</li> <li>Loop Diuretics – AHFS 402808</li> <li>Potassium-Sparing Diuretics – AHFS 402816</li> <li>Thiazide Diuretics – AHFS 402820</li> <li>Thiazide-Like Diuretics – AHFS 402824</li> <li>Vasopressin Antagonists – AHFS 402828</li> <li>Diuretics, Miscellaneous – AHFS 402892</li> <li>Alzheimer's Agents <ul> <li>Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current brands to be included: Aricept®, Exelon®, and Razadyne ER® only)</li> <li>Central Nervous System Agents, Miscellaneous – AHFS Class 289200 (current brands to be included: Aduhelm®, Namenda®, Namenda XR®, and Namzaric® only)</li> </ul> </li> <li>New Business</li> <li>Results of voting announced</li></ul>		
<ul> <li>Angiotensin-Converting Enzyme Inhibitors – AHFS 243204</li> <li>Angiotensin II Receptor Antagonists – AHFS 243208</li> <li>Renin Inhibitors – AHFS 243240</li> <li>Loop Diuretics – AHFS 402808</li> <li>Potassium-Sparing Diuretics – AHFS 402816</li> <li>Thiazide Diuretics – AHFS 402820</li> <li>Thiazide-Like Diuretics – AHFS 402824</li> <li>Vasopressin Antagonists – AHFS 402828</li> <li>Diuretics, Miscellaneous – AHFS 402892</li> <li>Alzheimer's Agents  <ul> <li>Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current brands to be included: Aricept®, Exelon®, and Razadyne ER® only)</li> <li>Central Nervous System Agents, Miscellaneous – AHFS Class 289200 (current brands to be included: Aduhelm®, Namenda®, Namenda XR®, and Namzaric® only)</li> </ul> </li> <li>6. New Business  <ul> <li>Results of voting announced</li></ul></li></ul>		
<ul> <li>Angiotensin II Receptor Antagonists – AHFS 243208</li> <li>Renin Inhibitors – AHFS 243240</li> <li>Loop Diuretics – AHFS 402808</li> <li>Potassium-Sparing Diuretics – AHFS 402816</li> <li>Thiazide Diuretics – AHFS 402820</li> <li>Thiazide-Like Diuretics – AHFS 402824</li> <li>Vasopressin Antagonists – AHFS 402828</li> <li>Diuretics, Miscellaneous – AHFS 402892</li> <li>Alzheimer's Agents <ul> <li>Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current brands to be included: Aricept®, Exelon®, and Razadyne ER® only)</li> <li>Central Nervous System Agents, Miscellaneous – AHFS Class 289200 (current brands to be included: Aduhelm®, Namenda®, Namenda XR®, and Namzaric® only)</li> </ul> </li> <li>6. New Business <ul> <li>Results of voting announced</li></ul></li></ul>		
<ul> <li>Renin Inhibitors – AHFS 243240</li> <li>Loop Diuretics – AHFS 402808</li> <li>Potassium-Sparing Diuretics – AHFS 402816</li> <li>Thiazide Diuretics – AHFS 402820</li> <li>Thiazide-Like Diuretics – AHFS 402824</li> <li>Vasopressin Antagonists – AHFS 402828</li> <li>Diuretics, Miscellaneous – AHFS 402892</li> <li>Alzheimer's Agents <ul> <li>Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current brands to be included: Aricept®, Exelon®, and Razadyne ER® only)</li> <li>Central Nervous System Agents, Miscellaneous – AHFS Class 289200 (current brands to be included: Aduhelm®, Namenda®, Namenda XR®, and Namzaric® only)</li> </ul> </li> <li>New Business <ul> <li>Results of voting announced</li> <li>Next meeting dates</li> <li>August 10, 2022</li> <li>November 9, 2022</li> </ul> </li> </ul>		
<ul> <li>Loop Diuretics – AHFS 402808</li> <li>Potassium-Sparing Diuretics – AHFS 402816</li> <li>Thiazide Diuretics – AHFS 402820</li> <li>Thiazide-Like Diuretics – AHFS 402824</li> <li>Vasopressin Antagonists – AHFS 402828</li> <li>Diuretics, Miscellaneous – AHFS 402892</li> <li>Alzheimer's Agents <ul> <li>Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current brands to be included: Aricept®, Exelon®, and Razadyne ER® only)</li> <li>Central Nervous System Agents, Miscellaneous – AHFS Class 289200 (current brands to be included: Aduhelm®, Namenda®, Namenda XR®, and Namzaric® only)</li> </ul> </li> <li>New Business</li> <li>Results of voting announced</li></ul>		
<ul> <li>Potassium-Sparing Diuretics – AHFS 402816</li> <li>Thiazide Diuretics – AHFS 402820</li> <li>Thiazide-Like Diuretics – AHFS 402824</li> <li>Vasopressin Antagonists – AHFS 402828</li> <li>Diuretics, Miscellaneous – AHFS 402892</li> <li>Alzheimer's Agents <ul> <li>Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current brands to be included: Aricept®, Exelon®, and Razadyne ER® only)</li> <li>Central Nervous System Agents, Miscellaneous – AHFS Class 289200 (current brands to be included: Aduhelm®, Namenda®, Namenda XR®, and Namzaric® only)</li> </ul> </li> <li>New Business <ul> <li>Results of voting announced</li></ul></li></ul>		
<ul> <li>Thiazide Diuretics – AHFS 402820</li> <li>Thiazide-Like Diuretics – AHFS 402824</li> <li>Vasopressin Antagonists – AHFS 402828</li> <li>Diuretics, Miscellaneous – AHFS 402892</li> <li>Alzheimer's Agents <ul> <li>Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current brands to be included: Aricept®, Exelon®, and Razadyne ER® only)</li> <li>Central Nervous System Agents, Miscellaneous – AHFS Class 289200 (current brands to be included: Aduhelm®, Namenda®, Namenda XR®, and Namzaric® only)</li> </ul> </li> <li>New Business <ul> <li>Results of voting announced.</li> <li>Next meeting dates</li> <li>August 10, 2022</li> <li>November 9, 2022</li> </ul> </li> </ul>		•
<ul> <li>Thiazide-Like Diuretics – AHFS 402824</li> <li>Vasopressin Antagonists – AHFS 402828</li> <li>Diuretics, Miscellaneous – AHFS 402892</li> <li>Alzheimer's Agents <ul> <li>Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current brands to be included: Aricept®, Exelon®, and Razadyne ER® only)</li> <li>Central Nervous System Agents, Miscellaneous – AHFS Class 289200 (current brands to be included: Aduhelm®, Namenda®, Namenda XR®, and Namzaric® only)</li> </ul> </li> <li>6. New Business <ul> <li>Results of voting announced</li> <li>Next meeting dates</li> <li>August 10, 2022</li> <li>November 9, 2022</li> </ul> </li> </ul>		
<ul> <li>Vasopressin Antagonists – AHFS 402828</li> <li>Diuretics, Miscellaneous – AHFS 402892</li> <li>Alzheimer's Agents <ul> <li>Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current brands to be included: Aricept®, Exelon®, and Razadyne ER® only)</li> <li>Central Nervous System Agents, Miscellaneous – AHFS Class 289200 (current brands to be included: Aduhelm®, Namenda®, Namenda XR®, and Namzaric® only)</li> </ul> </li> <li>6. New Business <ul> <li>Results of voting announced</li></ul></li></ul>		<ul> <li>Thiazide Diuretics – AHFS 402820</li> </ul>
<ul> <li>Diuretics, Miscellaneous – AHFS 402892</li> <li>Alzheimer's Agents <ul> <li>Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current brands to be included: Aricept®, Exelon®, and Razadyne ER® only)</li> <li>Central Nervous System Agents, Miscellaneous – AHFS Class 289200 (current brands to be included: Aduhelm®, Namenda®, Namenda XR®, and Namzaric® only)</li> </ul> </li> <li>New Business <ul> <li>Results of voting announced</li> <li>Next meeting dates</li> <li>August 10, 2022</li> <li>November 9, 2022</li> </ul> </li> </ul>		<ul> <li>Thiazide-Like Diuretics – AHFS 402824</li> </ul>
<ul> <li>Diuretics, Miscellaneous – AHFS 402892</li> <li>Alzheimer's Agents <ul> <li>Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current brands to be included: Aricept®, Exelon®, and Razadyne ER® only)</li> <li>Central Nervous System Agents, Miscellaneous – AHFS Class 289200 (current brands to be included: Aduhelm®, Namenda®, Namenda XR®, and Namzaric® only)</li> </ul> </li> <li>New Business <ul> <li>Results of voting announced</li> <li>Next meeting dates</li> <li>August 10, 2022</li> <li>November 9, 2022</li> </ul> </li> </ul>		<ul> <li>Vasopressin Antagonists – AHFS 402828</li> </ul>
<ul> <li>Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current brands to be included: Aricept®, Exelon®, and Razadyne ER® only)</li> <li>Central Nervous System Agents, Miscellaneous – AHFS Class 289200 (current brands to be included: Aduhelm®, Namenda®, Namenda XR®, and Namzaric® only)</li> <li>New Business</li> <li>Results of voting announced</li></ul>		
<ul> <li>Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current brands to be included: Aricept®, Exelon®, and Razadyne ER® only)</li> <li>Central Nervous System Agents, Miscellaneous – AHFS Class 289200 (current brands to be included: Aduhelm®, Namenda®, Namenda XR®, and Namzaric® only)</li> <li>New Business</li> <li>Results of voting announced</li></ul>		
<ul> <li>Central Nervous System Agents, Miscellaneous – AHFS Class 289200         (current brands to be included: Aduhelm®, Namenda®, Namenda XR®, and Namzaric® only)</li> <li>New Business</li> <li>Results of voting announced</li></ul>		o Parasympathomimetic (Cholinergic) Agents – AHFS Class 120400 (current
(current brands to be included: Aduhelm®, Namenda®, Namenda XR®, and Namzaric® only)  6. New Business  7. Results of voting announced		
Namzaric® only)  6. New Business  7. Results of voting announced		
6. New Business 7. Results of voting announced		
<ul> <li>7. Results of voting announced</li></ul>	6.	• •
<ul> <li>8. Next meeting dates</li> <li>August 10, 2022</li> <li>November 9, 2022</li> </ul>	7.	Results of voting announced
<ul><li>August 10, 2022</li><li>November 9, 2022</li></ul>		
• November 9, 2022		· · · · · · · · · · · · · · · · · · ·
·		
		• February 8, 2023

• May 3, 2023 9. Adjourn